Human IL-2 as a vaccine adjuvant
US5643565A · kind A · utility
20Cited by
1References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 24, 1995 |
| Grant date | Jul 1, 1997 |
| Priority date | — |
| Expiry date | May 24, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55533
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.